Multiple sclerosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD20 17
• CD19 9
• PPAR 0
• NLRP3 0
• STAT3 0
• BCMA 13
• NRF2 0
• TNF 0
• AQP4 0
• IL-17 0
• BTK 1
• GLP-1 2
• AMPK 0
• BDNF 1
• AKT 0
• IL-6 0
• mTOR 0
• CD40 0
• JAK 0
• PI3K 0
• STING 0
• TREM2 0
• PD-1 0
• IL-1 0
• IL-4 0
• SIRT1 0
• TLR4 0
• AXL 0
• CGRP 0
• CSF1R 0
• HIF-1 0
• IL-23 0
• VEGF 1
• COX-2 0
• CTLA-4 0
• CXCR4 0
• ERK 0
• HMGB1 0
• HSP90 0
• PD-L1 0
• TYK2 1
• APOE 0
• CCR5 0
• CTNNB1 0
• EGFR 0
• FOXP3 0
• GPX4 0
• IDO1 0
• JNK 0
• PARP 0
• PTEN 0
• TP53 1
• ACE2 0
• APP 0
• BCL-2 0
• BRD4 0
• C9orf72 0
• CDK4/6 0
• G6PD 0
• HDAC 0

EU-13 is a filter, not a ranking: it only narrows the list.

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

  NCT07609719· Genentech, Inc.· Source

• TARGET-EBV in MS: Targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate in multiple sclerosis

  2025-522140-40-00· Oslo University Hospital HF· Source

• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· Hoffmann-La Roche· Source

• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

  NCT04548999· Hoffmann-La Roche· Source

• Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

  NCT07510607· Ari Green· Source

• A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

  NCT04486716· Novartis Pharmaceuticals· Source

• Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

  NCT06529406· University of Colorado, Denver· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 38
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 563
• Machine Learning 43
• Deep Learning 32
• Cohort Studies 182
• Genome-Wide Association Study 84

• A candidate CD4⁺ T-cell gene expression panel for multiple sclerosis highlights MgADP-associated genes.

  Mult Scler Relat Disord, Sept 2026

• Machine learning identifies microbiome and clinical predictors of sustained weight loss following prolonged fasting.

  Genome Med, Sept 2026

• Machine Learning for Noninvasive Diagnosis of Neurodegenerative Diseases Using Retinal and Optic Nerve Imaging: A Comprehensive Review.

  Annu Rev Vis Sci, Sept 2026

• Multimodal MRI biomarkers and machine learning in neuromyelitis optica spectrum disorder: a review.

  Front Neurol, Aug 2026

• Machine Learning-Based Prediction of Sleep Quality in Patients with Multiple Sclerosis.

  Med Sci (Basel), Aug 2026

• Artificial intelligence-based monitoring of multiple sclerosis: A comprehensive survey.

  Mult Scler Relat Disord, Aug 2026

• Manual federated simulation for multiple sclerosis integrating XGBoost algorithm with SHAP explanation.

  Sci Rep, Jul 2026

• A multi-outcome prognostic score for therapeutic responses in multiple sclerosis.

  Rev Neurol (Paris), Jul 2026

• Microstructural changes in juxtacortical white matter regions and their relationship with PASAT score in multiple sclerosis: A proof of concept using machine learning.

  Mult Scler Relat Disord, Jun 2026

• Exploratory analysis of pupillography-based machine learning for assessing autonomic dysfunction in multiple sclerosis.

  Mult Scler Relat Disord, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.